Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | P4HTM | Q9NXG6 | 5/20 | 0.53 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.48 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31532327 | 1.00 | KMT2A (0.70) | KMT2AP4HTMP4HA1MIFKDM4E | |
| Hydrochloric Acid SCHEMBL9779782 | 0.98 | KMT2A (0.68) | KMT2AP4HTMP4HA1MIFKDM4E | |
| Hydrazine SCHEMBL28254112 | 0.96 | KMT2A (0.71) | KMT2AP4HTMP4HA1MIFKDM4E | |
| SCHEMBL27680503 | 0.86 | KMT2A (0.72) | KMT2AKDM4EALDH1A1MAPK1NPC1 | |
| SCHEMBL5131139 | 0.85 | KMT2A (0.53) | KMT2AP4HTMP4HA1MIFKDM4E | |
| SCHEMBL10328712 | 0.85 | KMT2A (0.51) | KMT2AP4HTMP4HA1MIFKDM4E | |
| SCHEMBL14684607 | 0.85 | KMT2A (0.51) | KMT2AP4HTMP4HA1MIFKDM4E | |
| SCHEMBL18275125 | 0.83 | KMT2A (0.50) | KMT2AP4HTMP4HA1MIFKDM4E | |
| SCHEMBL709672 | 0.82 | KMT2A (0.68) | KMT2AKDM4EALDH1A1MAPK1NPC1 | |
| SCHEMBL9779781 | 0.82 | KMT2A (0.68) | KMT2AKDM4EMAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | claimed |
| CN-113880762-B | Triacylamine derivatives containing 1,8-naphthalimide as well as preparation method and application thereof | 河北农业大学 | 2023-02-21 | — | — | CN | claimed |
| CN-113880762-A | 1, 8-naphthalimide-containing triacylamine derivatives, and preparation method and application thereof | 河北农业大学 | 2022-01-04 | — | — | CN | claimed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | claimed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | claimed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | claimed |
| CN-108516955-A | A kind of 5- trifluoromethyls -2- pyridine amides and the preparation method and application thereof | 上海凯爱网络科技有限公司 | 2018-09-11 | — | — | CN | claimed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | claimed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | claimed |
| US-9428456-B2 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2016-08-30 | — | — | US | claimed |
| CN-102652129-A | Amino oxazine derivatives | HOFFMANN LA ROCHE | 2012-08-29 | — | — | CN | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| CN-102471293-A | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG | 2012-05-23 | — | — | CN | claimed |
| CN-102421760-A | Dihydropyrimidinones useful as BACE2 inhibitors | HOFFMANN LA ROCHE | 2012-04-18 | — | — | CN | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| EP-0034917-B1 | 2-SUBSTITUTED-5-TRIFLUOROMETHYLPYRIDINES AND A PROCESS FOR PRODUCING THE SAME | ISHIHARA SANGYO KAISHA LTD. (JP) | 1984-08-08 | — | — | EP | claimed |
| EP-0034917-A1 | 2-Substituted-5-trifluoromethylpyridines and a process for producing the same | ISHIHARA SANGYO KAISHA LTD. (JP) | 1981-09-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | KMT2A 846/4885P4HTM 1684/4885P4HA1 993/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | KMT2A 846/4885P4HTM 1684/4885P4HA1 993/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | KMT2A 846/4885P4HTM 1684/4885P4HA1 993/4885 |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | KMT2A 3692/4885P4HTM 902/4885P4HA1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.